<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2025.1623753</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Preclinical characterisation of changes in cardiac function and circulating biomarkers following differential irradiation of thoracic volumes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kuburas</surname>
<given-names>Refik</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1341406/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ghita-Pettigrew</surname>
<given-names>Mihaela</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2005202/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Walls</surname>
<given-names>Gerard M.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kerr</surname>
<given-names>Brianna N.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brown</surname>
<given-names>Kathryn H.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3074932/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Facchi</surname>
<given-names>Cecilia</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McWilliam</surname>
<given-names>Alan</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1105937/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van Herk</surname>
<given-names>Marcel</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1088293/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Williams</surname>
<given-names>Kaye J.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1472836/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Butterworth</surname>
<given-names>Karl T.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/58351/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Patrick G. Johnston Centre for Cancer Research, Queens University Belfast</institution>, <addr-line>Belfast</addr-line>,&#xa0;<country>United Kingdom</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Division of Cancer, University of Manchester</institution>, <addr-line>Manchester</addr-line>,&#xa0;<country>United Kingdom</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Radiation Related Research, University of Manchester</institution>, <addr-line>Manchester</addr-line>,&#xa0;<country>United Kingdom</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Division of Pharmacy and Optometry, University of Manchester</institution>, <addr-line>Manchester</addr-line>,&#xa0;<country>United Kingdom</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Mohammad Rezaee, Johns Hopkins University, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Francesco P. Cammarata, Istituto di Bioimmagini e Sistemi Biologici Complessi (IBSBC-CNR), Italy</p>
<p>Ioannis Verginadis, University of Pennsylvania, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Karl T. Butterworth, <email xlink:href="mailto:k.butterworth@qub.ac.uk">k.butterworth@qub.ac.uk</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>06</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>15</volume>
<elocation-id>1623753</elocation-id>
<history>
<date date-type="received">
<day>06</day>
<month>05</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>06</day>
<month>06</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Kuburas, Ghita-Pettigrew, Walls, Kerr, Brown, Facchi, McWilliam, van Herk, Williams and Butterworth</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Kuburas, Ghita-Pettigrew, Walls, Kerr, Brown, Facchi, McWilliam, van Herk, Williams and Butterworth</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>The heart and lungs are critical organs at risk in patients receiving radiotherapy for thoracic tumours. Preclinical studies in rat models have provided evidence indicating consequential effects of lung radiation on the heart through vascular remodelling which leads to pulmonary arterial hypertension. In this study, we aimed to assess the impact of lung irradiation on a long-term model of cardiac base irradiation that recapitulates clinical observations of the heart base&#xa0;as a radiosensitive region and to understand relationships between cardiopulmonary irradiation and circulating cytokines profiles.</p>
</sec>
<sec>
<title>Methods</title>
<p>Female C57BL6J mice were irradiated under CT image-guidance targeting the heart base, right lung or co-irradiation of the heart base and the right lung. Mice were monitored by transthoracic echocardiography for 50-weeks after irradiation with lung histology and cytokine profiling at 10 and 50 weeks.</p>
</sec>
<sec>
<title>Results</title>
<p>Lung and heart co-irradiation leads to small changes in the cardiac function and histological changes in the right lung with distinct changes in serum cytokines for different irradiated volumes compared to heart irradiation.</p>
</sec>
<sec>
<title>Discussion</title>
<p>In contrast to previous studies in rat models, these data demonstrate a minimal contribution of lung irradiation to cardiac response in this model. Understanding the potential interplay between the heart and lungs is important in the context of optimising cardiac dose distributions that may increase lung doses and minimising the impact of lung dose on cardiac function.</p>
</sec>
</abstract>
<kwd-group>
<kwd>radiotherapy</kwd>
<kwd>preclinical model</kwd>
<kwd>cardiotoxicity</kwd>
<kwd>heart irradiation</kwd>
<kwd>lung irradiation</kwd>
<kwd>cardio-pulmonary</kwd>
<kwd>radiation-induced cardiac fibrosis</kwd>
<kwd>circulating biomarkers</kwd>
</kwd-group>
<contract-sponsor id="cn001">Medical Research Council<named-content content-type="fundref-id">10.13039/501100000265</named-content>
</contract-sponsor>
<counts>
<fig-count count="5"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="47"/>
<page-count count="11"/>
<word-count count="4563"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Radiation Oncology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Radiation-induced normal tissue toxicities are a complex challenge in the management of patients with non&#x2013;small cell lung cancer (NSCLC) treated with radiotherapy (RT) (<xref ref-type="bibr" rid="B1">1</xref>). During irradiation of the thorax, the proximity of the heart and lungs results in coincidental dose to both tissues. Whilst cardiac and pulmonary toxicities are independently well established, relatively little is known concerning potential interactions between these organs that could impact cumulative toxicities.</p>
<p>Treatment-related toxicities in the lung in the form of acute radiation pneumonitis (RP) or late occurring fibrosis (RF) are important dose limiting factors that directly impact patient outcomes and quality-of-life after treatment (<xref ref-type="bibr" rid="B2">2</xref>). In the heart, radiation-induced cardiotoxicity (RICT) can present as a range of pathologies including ischemia, arrhythmia, heart failure, valvulopathy, or pericardial disease months or years post-treatment (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). Historically, treatment planning has aimed to minimise the mean dose to both the heart and lung volumes based on the assumptions that each tissue is uniformly radiosensitive and responses are spatially independent (<xref ref-type="bibr" rid="B5">5</xref>). However, evidence suggests that distinct spatial dose volume effects in the lungs (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>) and heart (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>) can impact the probability of complications in these organs. Clinical studies suggest a strong spatial dependency with dose to specific cardiac substructures (<xref ref-type="bibr" rid="B10">10</xref>) associated with poor survival and cardiac outcomes (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>) yet the optimum dose constraints for cardiac substructures remain to be determined (<xref ref-type="bibr" rid="B10">10</xref>).</p>
<p>Understanding the complexity of spatial dose volume relationships in normal tissues highlights potential opportunities for optimisation by avoiding radiosensitive subvolumes to reduce the probability of complications without compromising target coverage or exceeding dose constraints in other organs at risk (OARs). This approach is being explored in lung cancer by defining a cardiac avoidance area (CAA) based on evidence linking excess dose to subvolumes and overall survival (<xref ref-type="bibr" rid="B12">12</xref>). An important consideration is the impact of avoidance on other OARs yet treatment planning evidence suggests that such an approach can significantly reduce heart dose with no significant increases in doses to other thoracic OARs including the lungs (<xref ref-type="bibr" rid="B13">13</xref>).</p>
<p>Previous experimental studies in rat models have provided evidence showing potential interactions between the heart and lungs following radiation exposure (<xref ref-type="bibr" rid="B14">14</xref>&#x2013;<xref ref-type="bibr" rid="B16">16</xref>). Irradiation of the heart results in changes in the cardiac vasculature and myocardium leading to cardiac dysfunction which also causes pulmonary interstitial oedema. Lung irradiation can indirectly impair cardiac function through radiation-induced pulmonary hypertension and pulmonary perivascular oedema. In addition, co-irradiation can enhance cardiac dysfunction via both mechanisms (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B17">17</xref>). Further studies are needed to characterise the interplay between the cardiac and pulmonary systems, and to better understand the spatial dose volume relationships in these organs leveraging the advantages of image-guided irradiators in preclinical models (<xref ref-type="bibr" rid="B18">18</xref>&#x2013;<xref ref-type="bibr" rid="B21">21</xref>).</p>
<p>We have established and characterised a translationally relevant mouse model of heart base irradiation that recapitulates clinical observations identifying the heart base as a radiosensitive subvolume associated with functional loss (<xref ref-type="bibr" rid="B22">22</xref>&#x2013;<xref ref-type="bibr" rid="B24">24</xref>). In the current study, we aimed to apply this model to investigate potential interactions between the heart and lungs following radiation exposure by assessing changes in cardiac function, lung histology and circulating biomarkers following irradiation of the heart or co-irradiation of the heart and lungs.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<label>2</label>
<title>Materials and methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Animals and maintenance</title>
<p>Female C57BL6J mice, 12&#x2013;16 weeks-old (Charles River Laboratories, Oxford, UK) were housed under controlled conditions (12hr light-dark cycle, 21&#xb0;C) in standard caging with 3&#x2013;5 littermates and received a standard laboratory diet (Teklad, Envigo, UK) with water a<italic>d libitum</italic>. Mice were randomly assigned to experimental groups prior to irradiation. Animal numbers were chosen to give power to detect differences in myocardial performance index (MPI) of 25% with a power of 80% for a 2-sided equality test with a significance threshold of 0.05 which required at least six mice per group. In this study we used 8 mice per group for each timepoint, with aged matched controls at week 50.</p>
<p>Mouse weight was monitored throughout the experiment, with no deviation outside the tolerated weight loss of &lt;15%. All animal research and experiments carried out at Queen&#x2019;s University Belfast were approved by the local Animal Welfare Ethical Review Board (AWERB) and a Department of Health Project License (PPL 2935). All experimental procedures were carried out in accordance with the Home Office Guidance on the Operation of the Animals (Scientific Procedures) Act 1986, published by His Majesty&#x2019;s Stationary Office, London. Animal studies are reported in compliance with the ARRIVE guidelines and suggested reporting requirements for preclinical cardiac irradiation studies (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B26">26</xref>).</p>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Irradiation protocol</title>
<p>Prior to irradiation mice were anaesthetised with ketamine (100 mg/kg) and xylazine (10 mg/kg) by intraperitoneal injection. Mice were randomized prior to irradiation to either a control non-irradiated group, heart base irradiation with 16 Gy, right lung irradiation with 10 Gy or a combined heart base (16 Gy) and right lung (10 Gy) irradiation. Mice were irradiated with 220 kVp X-rays under cone beam computed tomography (CBCT) image guidance using a SARRP (Xstrahl Life Sciences) calibrated using the Institute of Physics and Engineering in Medicine and Biology (IPEMB) code of practice (<xref ref-type="bibr" rid="B27">27</xref>). For heart base irradiation, the cranial third of the heart was localised using CBCT imaging and an anterior-posterior field arrangement was created using a 3 x 9 mm collimator with a dose rate of 2.67 &#xb1; 0.11 Gy/min as previously described (<xref ref-type="bibr" rid="B22">22</xref>). Dose to the upper region of the right lung was delivered using a 5 x 5 mm collimator at a dose rate of 2.75 &#xb1; 0.23 Gy/min in a similar anterior-posterior beam geometry. Dose-volume histograms (DVHs) were retrospectively calculated for each animal (Muriplan, Xstrahl Inc, Suwannee, GA, USA). A schematic overview of the study including the DVHs and endpoints is shown in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Schematic overview of the experimental configurations targeting different thoracic volume in the heart, right lung and co-irradiation. Mice were randomized to heart base irradiation (16 Gy), right lung irradiation (10 Gy), or co-irradiation of the heart base (16 Gy) and right lung (10 Gy) <bold>(A)</bold>. Dose volume histograms (DVHs) and mean heart doses (MHD) for each of the targets are shown in <bold>(B, C)</bold>, respectively.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-15-1623753-g001.tif">
<alt-text content-type="machine-generated">Diagram showing the  effect of different radiation doses on heartand  lung  volumes. Panel  A depicts three conditions: heart base with 16 Gy, heart base and right lung  with 16 Gy and  10 Gy respectively, and  only the  right lung with 10 Gy. Panel B includes dose-volume histograms showing the  percentage volume of the  heart and  lungs  at various  doses. Panel  C presents bar graphs of mean doses for the  heart, left lung, and  right lung  under each condition.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>Transthoracic echocardiography</title>
<p>TTE was performed at baseline and 50-weeks after irradiation using Vevo770<sup>&#xae;</sup> ultrasound system, with a 45 MHz RMV707B scan head (FUJIFILM, VisualSonics Inc. ON, Canada). Mice were anaesthetised using inhalant isoflurane (3% for induction, and 1.5% during imaging). Left ventricular (LV) systolic and diastolic metrics were measured in triplicate for each mouse. LV ejection fraction (EF) and fractional shortening (FS) were calculated from the M-mode parasternal short-axis view, as previously described (<xref ref-type="bibr" rid="B28">28</xref>). Pulse-wave Doppler imaging was used to measure the early and late filling ratio (E/A ratio). MPI was calculated as previously described (<xref ref-type="bibr" rid="B28">28</xref>). Observers were blinded to experimental groups during data collection and analysis.</p>
</sec>
<sec id="s2_4">
<label>2.4</label>
<title>Histopathological analysis of the irradiated right lung</title>
<p>Lung were harvested at 10 and 50-weeks after irradiation. After fixation, samples were processed, paraffin embedded and cut into 5 &#xb5;m sections for histological staining and evaluation. Pulmonary perivascular and interstitial oedema were assessed using the semi-quantitative scoring previously reported (<xref ref-type="bibr" rid="B17">17</xref>). Perivascular oedema was scored between 0-2 (2 indicating severe perivascular oedema) for at least 5 large vessels and 20 small vessels across the right lung. For interstitial oedema, scores from 0-3 (3 severe interstitial oedema) were given according to the level damage severity across 4 different fields of view (400 x 400 &#xb5;m) across the right lung (<xref ref-type="bibr" rid="B17">17</xref>). Pulmonary vessel wall thickness was measured for 30 randomly chosen vessels across in the upper right lung as previously described (<xref ref-type="bibr" rid="B14">14</xref>). Fibrosis was measured by type I collagen staining using Masson&#x2019;s Trichrome (Abcam, ab150686) as outlined in <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material S1</bold>
</xref>. Scores were recorded from 6 different regions within or outside of the irradiated field of the heart or right lung for 4 mice per experimental group and &#x2265;2 age matched control animals. Lung fibrosis was quantified using Matlab R2022a as previously described (<xref ref-type="bibr" rid="B29">29</xref>).</p>
</sec>
<sec id="s2_5">
<label>2.5</label>
<title>Analysis of cytokine expression and pathway enrichment</title>
<p>Mouse XL Proteome Profiler Cytokine arrays (ARY028, R&amp;D Systems, UK) were performed to simultaneously characterise the expression of 111 cytokine targets. Each cytokine was present in duplicate on the membrane. Serum used for analysis was isolated from blood samples at weeks 10 and 50 from irradiated mice alongside age-matched controls. Cytokine arrays were performed according to the manufacturer&#x2019;s instructions using pooled serum samples for each treatment group (control n=2, heart n=6, lung n=6, heart and lung n=6). Membranes were developed using the GBox Imager and GeneSys software (V1.4.60) (Synotics Ltd, Cambridge, UK). Quantification of signal intensities was performed with GeneTools software (V4.3.14) (Synotics Ltd, Cambridge, UK), and densitometry values for spots were normalised to that of the age-matched controls. Cytokine arrays were completed in one independent experiment. Proteins which satisfied a threshold of <italic>&gt;</italic> 2- and <italic>&lt;</italic> 0.5-fold change were considered differentially expressed. These proteins were transformed into their corresponding gene names for pathway enrichment analysis using Enrichr (<xref ref-type="bibr" rid="B30">30</xref>).</p>
</sec>
<sec id="s2_6">
<label>2.6</label>
<title>Statistical analysis</title>
<p>Data are presented as the average for the entire experimental arm &#xb1; standard error. Error bars represent the standard error of the mean (SEM). Statistical analysis was performed using student&#x2019;s t-test unless otherwise stated. Statistical significances are represented as <italic>p</italic> &lt; 0.05 = *; <italic>p &lt;</italic>0.01 = **; <italic>p &lt;</italic>0.001 = ***; and <italic>p &lt;</italic>0.0001 = ****. All bar graphs, heatmaps, and principal component analysis (PCA) plots were created using GraphPad Prism (V9.2.0).</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Result</title>
<sec id="s3_1">
<label>3.1</label>
<title>Cardiac function is impaired by heart base irradiation and is not impacted by lung co-irradiation</title>
<p>Cardiac systolic and diastolic parameters were assessed following the irradiation of different thoracic volumes. No statistically significant changes in cardiac function parameters were observed between control and irradiated mice at 10 weeks after irradiation (<xref ref-type="supplementary-material" rid="SF1">
<bold>Supplementary Figure S1</bold>
</xref>). At 50 weeks after irradiation, several changes in cardiac function were observed between control and irradiated animals (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>). Systolic function measured by EF was significantly lower after irradiation of the heart base and co-irradiation of the heart base and right lung (p&lt;0.004) compared to control animals. A small but significant decrease in FS was observed only for heart base irradiation compared to control animals (p=0.036). Diastolic function measured by the E/A ratio was significantly lower after heart base and co-irradiation of the heart base and right lung (<italic>p</italic> =0.038). MPI is a measure of the overall performance of the heart integrating both systolic and diastolic function that increases with cardiac dysfunction. MPI was significantly increased in all irradiated groups with much higher increases in the heart base and co-irradiation groups compared to the control group (p&lt;0.001). Overall, these data show a significant effect of heart base irradiation on cardiac function with co-irradiation of the right lung having minimal impact on the observed responses at 50 weeks after irradiation.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Longitudinal variations in cardiac functional parameters following irradiation of different thoracic volumes at 50 weeks after irradiation (Ejection fraction, EF, <bold>(A)</bold> Fractional shortening, FS. <bold>(B)</bold> E/A Ratio, <bold>(C)</bold> Myocardial Performance Index, <bold>(D)</bold>]. No significant changes in parameters were observed at 10 weeks after irradiation (<xref ref-type="supplementary-material" rid="SF1">
<bold>Supplementary Figure S1</bold>
</xref>). Data presented are an average of 6 mice per treatment group &#xb1; SEM against age-matched control values. Significance values were classified as *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01 and ***<italic>p</italic> &lt; 0.001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-15-1623753-g002.tif">
<alt-text content-type="machine-generated">Bar charts labeled A to D display cardiovascular metrics acrossfour groups: Control, Heart,  Heart+Lung, and  Lung. Chart  A shows ejection fraction percentage, with Control signi&#xfb01;cantly higher.  Chart  B depicts fractional shortening percentage, with Control slightly higher.  Chart  C illustrates E/A ratio, with varied signi&#xfb01;cance. Chart  D shows MPI, where Heart  and  Heart+Lung are signi&#xfb01;cantly elevated compared to Control. Asterisks indicate levels of statistical signi&#xfb01;cance.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>Heart and lung co-irradiation modulates histological changes in the lung</title>
<p>Histological changes were assessed in the irradiated right lung at 10 and 50 weeks after the irradiation of different thoracic target volumes (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A-F</bold>
</xref>). At 10 weeks after irradiation, all groups showed a significant increase in pulmonary oedema compared to control animals (p&lt;0.05) with the largest increase observed in the co-irradiation group. Irradiation of the heart and lungs as individual targets showed comparable levels of response that were not significantly different (p &gt; 0.05, Panel A). A small but significant increase in pulmonary vessel wall thickness was only detected following heart base irradiation. Heart and heart lung co-irradiation showed small but significant increases in fibrosis that was higher than irradiation of the lung as a single target (Panel C). Similar trends were observed at 50 weeks after irradiation showing significant increases in pulmonary oedema compared to control animals (p&lt;0.01) with similar increases in the heart and co-irradiation groups. A small but significant increase in pulmonary vessel wall thickness was only detected following co-irradiation whilst the levels of fibrosis were significantly higher in the heart and co-irradiation groups. These data suggest small but significant histological changes in lung that are dependent on the irradiation of the heart. Represantative images from histology analysis are shown in <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure 2</bold>
</xref>.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Histological changes and collagen levels in the irradiated right lung at 10 and 50 weeks following irradiation of different thoracic volumes. The levels of perivascular oedema and pulmonary vessel wall thickness were assessed following H &amp; E staining <bold>(A, B, D, E)</bold>. Fibrosis was assessed by type I collagen staining <bold>(C, F)</bold>. Data presented are an average of 6 mice per treatment group (n = 2 for 50-week control group) &#xb1; SEM against age-matched control values. Significance values were classified as *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01 and ***<italic>p</italic> &lt; 0.001. Scale bar = 50 &#xb5;m.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-15-1623753-g003.tif">
<alt-text content-type="machine-generated">Graphs comparing perivascular edema scores, wall thickness, andcollagen deposition in control, heart, heart and  lung, and  lung groups at ten  and  &#xfb01;fty weeks. Signi&#xfb01;cant differences are indicated, showing changes over  time  for each metric across different treatment groups.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Heart and lung co-irradiation leads to differential changes in the levels of circulating cytokines</title>
<p>Cytokine analysis was performed on serum samples obtained at 10 and 50-weeks after irradiation (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>). Heatmaps show the fold changes in the expression of 111 cytokines compared to age-matched controls at the respective timepoints for each target volume (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4A, B</bold>
</xref>). These data highlight distinct changes for each of the irradiated volumes and at each time point with an overall trend showing decreased cytokine expression following irradiation of the lungs compared to the other volumes. PCA was used to identify similarities in modulated cytokine expression between the different irradiated volumes (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4C</bold>
</xref>). The PCA plot shows clustering of the individual heart and lung volumes within each timepoint suggesting similar cytokine modulatory effects. The observed changes occurred predominantly across PC2. In contrast, combined heart and lung irradiation has a unique effect on cytokine expression at both timepoints, reflected by the lack of clustering and the individuality of these data points. These changes occurred across PC1.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Expression of circulating inflammatory cytokines at 10 and 50 weeks following irradiation of different thoracic volumes. Heatmaps of fold changes in cytokine expression compared to age-matched controls are shown at 10 <bold>(A)</bold> and 50 <bold>(B)</bold> weeks after irradiation of the heart, heart and lung co-irradiation and the right lung. A principal component analysis (PCA) plot of the samples is shown in <bold>(C)</bold> Changes in the levels of biomarkers with known cardio-pulmonary functions are shown in <bold>(D)</bold>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-15-1623753-g004.tif">
<alt-text content-type="machine-generated">Heatmaps and  graphs depict gene expression data  from  heart andlung  tissues. Panels  A and  B show  expression levels, with color  scales indicating intensity. Panel  C is a PCA plot  visualizing sample clustering by tissue  type  and  time.  Panel  D  includes bar graphs for CD14, PD-ECGF, and  Leptin, comparing fold changes at ten  and &#xfb01;fty weeks for heart, lung, and  combined tissues.</alt-text>
</graphic>
</fig>
<p>Changes in specific cytokine levels demonstrated differential responses following irradiation of the different target volumes (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4D</bold>
</xref>). In particular, a clear difference was observed in the levels of CD14 for the different irradiated volumes. At 10 weeks, CD14 showed a &gt;2-fold upregulation following irradiation of the heart yet the level was several orders of magnitude lower following co-irradiation or irradiation of the lung only. However, at 50 weeks, no major changes in CD14 were observed. Platelet-derived endothelial cell growth factor (PD-ECGF) also showed a pronounced volume dependent response. At 10 weeks, PD-ECGF showed &gt; 2-fold upregulation following co-irradiation yet the levels were down regulated following irradiation of the heart or lung. At 50 weeks, the levels of PD-ECGF were lower in the co-irradiation group, elevated in the heart group and unchanged in the lung group compared to the level at 10 weeks. At 10 weeks, the levels of leptin remained unchanged compared to controls in the heart and co-irradiation groups but were lower in the lung irradiated group. At 50 weeks, the levels increase close to 2-fold following heart and lung irradiation as single targets but decreased in the co-irradiation group. Overall, these data highlight distinct changes in the circulating inflammatory proteome that are dependent on the irradiated target volume and time after irradiation.</p>
<p>Differential cytokine analysis was performed by applying a threshold of &gt; 2-fold changes at 10 and 50 weeks (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5A</bold>
</xref>). At 10 weeks, 3, 15 and 26 cytokines were found to be volume-specific for the heart, heart and lung, and lung irradiations, respectively. At&#xa0;50 weeks, 9, 9 and 13, cytokines were found to be volume-specific for the heart, heart and lung, and lung, respectively. The identified volume specific cytokines were then used for pathway enrichment analysis (<xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5B, C</bold>
</xref>). For all of the irradiated volumes at 10 and 50 weeks, the most enriched pathway was proinflammatory and profibrotic mediators. At 10 weeks, lung fibrosis was enriched following lung only and co-irradiation but not for heart irradiation, however, at 50 weeks, lung fibrosis was enriched in the heart and lung irradiation groups. These data support the underlying biological pathways involved in the inflammatory response of the respective tissues and suggest a potential interaction between the heart and lung that acts to suppress fibrosis when the organs are co-irradiated.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Analysis of volume-specific cytokines and associated biological pathways at 10 and 50 weeks following irradiation of different thoracic volumes. Cytokines showing &gt; 2-fold changes for the different volumes at 10 and 50 weeks <bold>(A)</bold> with pathway enrichment analysis at the respective timepoints <bold>(B, C)</bold>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-15-1623753-g005.tif">
<alt-text content-type="machine-generated">Venn diagrams and  bar charts displaying  gene and  pathway datafor heart, heart &amp; lung, and  lung tissues at 10 and  50 weeks. Part A shows overlap and unique counts of genes using  colored circles.  Part B and  C feature bar charts showing pathway names in different colors corresponding to tissues, with pathway details.</alt-text>
</graphic>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>The heart and lungs are critical organs at risk in patients receiving RT for thoracic cancers. Current treatment planning practice considers the risk of complications in these tissues independently according to organ specific dose constraints. Previous preclinical studies in rat models have demonstrated potential interactions between the heart and lungs following lung irradiation characteristic of pulmonary arterial hypertension (PAH). This process is driven by pulmonary vascular remodelling leading to arterial hypertension and increased burden on the right ventricle (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B17">17</xref>). In the current study, we aimed to assess the impact of lung irradiation on cardiac radiation response and to identify changes in the circulating biomarkers following irradiation of the heart or co-irradiation of the heart and lungs.</p>
<p>Using CT image guidance to target the base of the heart, our data showed distinct functional loss of systolic and diastolic parameters and MPI changes at 50 weeks after irradiation consistent with our previous observations in this model (<xref ref-type="bibr" rid="B22">22</xref>). These changes may be due to the targeting of critical structures located in the base of the heart including the coronary arteries, pulmonary arterial trunk and pulmonary veins, or pacemaker tissues including the sinoatrial and atrioventricular nodes. Compared to age matched control animals, co-irradiation of the heart base and right lung resulted in small but significant changes in EF, E/A ratio and MPI that were smaller than those observed for irradiation of the heart alone. The unexpected small increases in EF, FS and E/A ratio compared to heart irradiated animals suggests a potential sparing of cardiac function when the right lung is irradiated. These observations were supported by an upwards trend in MPI indicating improved global cardiac performance for co-irradiation compared irradiation of the heart. These data suggest subtle alterations in the timing and overall efficiency of the cardiac cycle due to subclinical dysfunction, combined systolic and diastolic impairment, or regional changes that are not captured by global measures. In contrast to previous studies in rats (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B31">31</xref>), these findings show a minimal contribution of lung irradiation to cardiac response in this model. Further validation is required potentially using cardiac strain to measure deformation of the myocardium during the cardiac cycle. We have recently demonstrated this&#xa0;approach as an early predictive biomarker of cardiac function&#xa0;(<xref ref-type="bibr" rid="B23">23</xref>), however, this technology was not available in our laboratory at the time of investigation.</p>
<p>Histological changes in the lung showed small but variable changes in perivascular oedema, wall thickness and collagen levels following irradiation of the different volumes at 10 and 50 wks. Minimal changes in vessel wall thickness at were observed at both times points. Whilst some of the observed changes are statistically significant, they are &lt; 2% in most cases. These data suggest minimal impacts of heart irradiation on the histology of the lung and are likely to have limited functional consequences on heart through the development of PAH in this model.</p>
<p>The mechanisms underlying the indirect effects of lung irradiation on the heart remain to be fully understood. Given the central role of inflammatory cytokines in mediating radiation-induced pneumopathy (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>), cytokine profiling was conducted on serum samples at 10 and 50 weeks after irradiation to characterise changes in circulating proteins and to identify potential mechanisms of response. PCA showed clustering of samples for the individual heart and lung volumes at each timepoint suggesting similar cytokine modulatory effects. In contrast, combined heart and lung irradiation showed a distinct expression profile at both timepoints highlighting volume specific responses presented as Venn diagrams in <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>.</p>
<p>At 10 weeks, differential expression analysis identified cytokine changes specific to each volume and identified upregulation of CD14 following heart radiation. CD14 is a glycoprotein receptor that has been shown to promote macrophage activation and is closely linked to myocardial dysfunction and adverse remodelling (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B35">35</xref>). In the plasma, soluble CD14 (sCD14) arises from proteolytic cleavage of the membrane-bound form (<xref ref-type="bibr" rid="B36">36</xref>). Clinical studies have reported significant associations between sCD14 levels, atherosclerotic cardiovascular disease and heart failure (<xref ref-type="bibr" rid="B37">37</xref>). The association of sCD14 with cardiac radiation response has not been reported and our data suggest sCD14 as a potential biomarker of RICT. Following lung irradiation, leptin was identified as differentially down-regulated. Leptin is a hormone secreted by adipocytes that has been shown to promote lung cancer progression and therapeutic resistance and thus may be considered a therapeutic target following lung-targeted RT (<xref ref-type="bibr" rid="B38">38</xref>&#x2013;<xref ref-type="bibr" rid="B40">40</xref>). Finally, co-irradiation of the heart and lung resulted in differential upregulation of PD-ECGF. PD-ECGF is a pro-angiogenic factor that is involved in constrictive vascular remodelling in the heart (<xref ref-type="bibr" rid="B41">41</xref>). This suggests that PD-ECGF may be an important molecule involved in radiation response of the heart and lung. Whilst these exploratory data are informative in characterising cytokine driven changes following thoracic irradiation, further validation is required in clinical samples.</p>
<p>To further understand the biological pathways involved follow irradiation, pathway enrichment analysis of volume specific cytokines showing a &gt;2 fold change was conducted at 10 and 50 weeks. At 10 weeks after irradiation, lung fibrosis was highly enriched following lung irradiation and co-irradiation in agreement with the histological trends. Despite causing high levels of lung fibrosis, this pathway was not enriched for heart-only irradiation at 10 weeks but was enriched at 50 weeks. The impact of heart base irradiation on pericardial and myocardial fibrosis was also reflected by the enrichment of osteopontin (OPN) signalling via the upregulation of MMP-9 as this is associated with cardiac remodelling and fibrosis (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B43">43</xref>). In contrast, OPN expression was downregulated at 10 weeks after co-irradiation, potentially supporting the observed trend in cardiac functional parameters. Also, enrichment of TGF-&#x3b2; signalling at 50 weeks following heart and lung co-irradiation may be due to the upregulation of MMP-9 which activates TGF-&#x3b2; (<xref ref-type="bibr" rid="B44">44</xref>). This also correlates with downregulation of IFN-&#x3b3; which is suppressed by TGF-&#x3b2; (<xref ref-type="bibr" rid="B45">45</xref>). These results correlate with collagen deposition in the right lung following heart and lung combined irradiation. These data highlight the complexity of radiation-induced changes in cytokine signalling for different thoracic volumes and have value in identifying the underlying biological processes involved.</p>
<p>Previously, lung irradiation was found to induce PAH with a dose and volume dependency, with severe pulmonary hypertension associated with a large lung volume (75%) irradiated with a high dose of 17 Gy (<xref ref-type="bibr" rid="B14">14</xref>). Our study failed to definitively demonstrate that radiation effects on the lung contribute to cardiotoxicity and is subject to several limitations. CT image guidance was used to irradiate a small lung volume with a dose of 10 Gy. In contrast, most previous studies irradiated lung volumes &gt;25% with doses of 12 and 20 Gy (<xref ref-type="bibr" rid="B46">46</xref>) and so the lack of an observed phenotype may be due to the irradiation of a small volume at a subthreshold dose. Also, changes in lung function were not assessed using techniques such as whole-body plethysmography (WBP) and would be informative in understanding the complex interplay following heart and lung irradiations (<xref ref-type="bibr" rid="B47">47</xref>). Finally, additional validation of the volume specific cytokine changes is required under different irradiation conditions to demonstrate potential value as biomarkers of response. This study was conducted only in female mice and is subject to sex bias.</p>
<p>Overall, this study presents mild effects after heart and lung co-irradiation. While these results offer limited insight into these effects at lower doses and volumes than previously reported, they map out a potential dose-volume effect for doses similar to clinical dose baths delivered to normal tissues for a thoracic tumour. Despite these limitations, our study raises questions concerning the inter-relationships between lung and heart doses that merits further investigation. Understanding this potential interplay is important in the context of optimising cardiac dose distributions that may increase lung doses and minimising the impact of lung dose on cardiac function.</p>
</sec>
</body>
<back>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>Data is available upon request from corresponding author.</p>
</sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The animal study was approved by Animal Welfare Ethical Review Board (AWERB), Queen&#x2019;s University Belfast. The study was&#xa0;conducted in accordance with the local legislation and institutional requirements.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>RK: Writing &#x2013; review &amp; editing, Writing &#x2013; original draft, Investigation, Formal Analysis, Data curation. MG: Visualization, Data curation, Formal Analysis, Methodology, Writing &#x2013; review &amp; editing, Investigation, Writing &#x2013; original draft. GW: Writing &#x2013; review &amp; editing, Conceptualization, Writing &#x2013; original draft, Formal Analysis. BK: Visualization, Methodology, Data curation, Writing &#x2013; review &amp; editing, Formal Analysis, Writing &#x2013; original draft. KB: Writing &#x2013; review &amp; editing, Writing &#x2013; original draft, Data curation, Formal Analysis, Methodology. CF: Writing &#x2013; original draft, Formal Analysis, Writing &#x2013; review &amp; editing. AM: Writing &#x2013; original draft, Conceptualization, Funding acquisition, Writing &#x2013; review &amp; editing, Formal Analysis. Mv: Writing &#x2013; original draft, Formal Analysis, Writing &#x2013; review &amp; editing, Funding acquisition, Conceptualization. KW: Funding acquisition, Writing &#x2013; review &amp; editing, Writing &#x2013; original draft, Methodology, Formal Analysis, Conceptualization. KB: Investigation, Funding acquisition, Writing &#x2013; review &amp; editing, Conceptualization, Project administration, Writing &#x2013; original draft, Supervision, Methodology.</p>
</sec>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research and/or publication of this article. This work was funded by the Medical Research Council (Award Ref : MR/V009605/1).</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
</sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="SM1" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fonc.2025.1623753/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fonc.2025.1623753/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Image1.tif" id="SF1" mimetype="image/tiff">
<label>Supplementary Figure&#xa0;1</label>
<caption>
<p>The impact of thoracic irradiation configurations on cardiac systolic and diastolic parameters at 10 weeks after irradiation. <bold>(a)</bold> EF, <bold>(b)</bold> FS, <bold>(c)</bold> E/A Ratio, and <bold>(d)</bold> MPI were evaluated in mice after heart base, heart and lung, and lung only irradiations. Data presented are an average of 6 mice per treatment group &#xb1; SEM against age-matched control values. Significance values were classified as *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01 and ***<italic>p</italic> &lt; 0.001.</p>
</caption>
</supplementary-material>
<supplementary-material xlink:href="Image2.tif" id="SF2" mimetype="image/tiff">
<label>Supplementary Figure&#xa0;2</label>
<caption>
<p>Representative images of lung tissue after irradiation showing H&amp;E staining (panel A) and Masson&#x2019;s Trichrome staining (Panel B).</p>
</caption>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname> <given-names>GM</given-names>
</name>
<name>
<surname>Bergom</surname> <given-names>C</given-names>
</name>
<name>
<surname>Mitchell</surname> <given-names>JD</given-names>
</name>
<name>
<surname>Rentschler</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Hugo</surname> <given-names>GD</given-names>
</name>
<name>
<surname>Samson</surname> <given-names>PP</given-names>
</name>
<etal/>
</person-group>. <article-title>Cardiotoxicity following thoracic radiotherapy for lung cancer</article-title>. <source>Br J Cancer</source>. (<year>2024</year>), <page-range>311&#x2013;25</page-range>. Springer Nature. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41416-024-02926-x</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>K&#xe4;smann</surname> <given-names>L</given-names>
</name>
<name>
<surname>Dietrich</surname> <given-names>A</given-names>
</name>
<name>
<surname>Staab-Weijnitz</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Manapov</surname> <given-names>F</given-names>
</name>
<name>
<surname>Behr</surname> <given-names>J</given-names>
</name>
<name>
<surname>Rimner</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Radiation-induced lung toxicity - Cellular and molecular mechanisms of pathogenesis, management, and literature review</article-title>. <source>Radiat Oncol</source>. (<year>2020</year>) <volume>15</volume>:<page-range>1&#x2013;16</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13014-020-01654-9</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitchell</surname> <given-names>JD</given-names>
</name>
<name>
<surname>Cehic</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Morgia</surname> <given-names>M</given-names>
</name>
<name>
<surname>Bergom</surname> <given-names>C</given-names>
</name>
<name>
<surname>Toohey</surname> <given-names>J</given-names>
</name>
<name>
<surname>Guerrero</surname> <given-names>PA</given-names>
</name>
<etal/>
</person-group>. <article-title>Cardiovascular manifestations from therapeutic radiation: A multidisciplinary expert consensus statement from the international cardio-oncology society</article-title>. <source>JACC: Cardio Oncol</source>. (<year>2021</year>) <volume>3</volume>:<page-range>360&#x2013;80</page-range>. Elsevier Inc. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaccao.2021.06.003</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quintero-Martinez</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Cordova-Madera</surname> <given-names>SN</given-names>
</name>
<name>
<surname>Villarraga</surname> <given-names>HR</given-names>
</name>
</person-group>. <article-title>Radiation-induced heart disease</article-title>. <source>J Clin Med</source>. (<year>2022</year>) <volume>11</volume>:<page-range>1&#x2013;15</page-range>. MDPI. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/jcm11010146</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voshart</surname> <given-names>DC</given-names>
</name>
<name>
<surname>Wiedemann</surname> <given-names>J</given-names>
</name>
<name>
<surname>van Luijk</surname> <given-names>P</given-names>
</name>
<name>
<surname>Barazzuol</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Regional responses in radiation-induced normal tissue damage</article-title>. <source>Cancers</source>. (<year>2021</year>) <volume>13</volume>:<fpage>1</fpage>&#x2013;<lpage>21</lpage>. MDPI AG. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cancers13030367</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Graham</surname> <given-names>MV</given-names>
</name>
<name>
<surname>Purdy</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Emami</surname> <given-names>B</given-names>
</name>
<name>
<surname>Harms</surname> <given-names>W</given-names>
</name>
<name>
<surname>Bosch</surname> <given-names>W</given-names>
</name>
<name>
<surname>Lockett</surname> <given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>1999</year>) <volume>45</volume>:<page-range>323&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0360-3016(99)00183-2</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yorke</surname> <given-names>ED</given-names>
</name>
<name>
<surname>Jackson</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rosenzweig</surname> <given-names>KE</given-names>
</name>
<name>
<surname>Merrick</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Gabrys</surname> <given-names>D</given-names>
</name>
<name>
<surname>Venkatraman</surname> <given-names>ES</given-names>
</name>
<etal/>
</person-group>. <article-title>Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy</article-title>. (<year>2002</year>) <volume>54</volume>:<page-range>329&#x2013;39</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0360-3016(02)02929-2</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atkins</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Rawal</surname> <given-names>B</given-names>
</name>
<name>
<surname>Chaunzwa</surname> <given-names>TL</given-names>
</name>
<name>
<surname>Lamba</surname> <given-names>N</given-names>
</name>
<name>
<surname>Bitterman</surname> <given-names>DS</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>CL</given-names>
</name>
<etal/>
</person-group>. <article-title>Cardiac radiation dose, cardiac disease, and mortality in patients with lung cancer</article-title>. <source>J Am Coll Cardiol</source>. (<year>2019</year>) <volume>73</volume>:<page-range>2976&#x2013;87</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jacc.2019.03.500</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desai</surname> <given-names>N</given-names>
</name>
<name>
<surname>Currey</surname> <given-names>A</given-names>
</name>
<name>
<surname>Kelly</surname> <given-names>T</given-names>
</name>
<name>
<surname>Bergom</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Nationwide trends in heart-sparing techniques utilized in radiation therapy for breast cancer</article-title>. <source>Advancesradonc</source>. (<year>2019</year>) <volume>4</volume>:<page-range>246&#x2013;52</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.adro.2019.01.001</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bowen Jones</surname> <given-names>S</given-names>
</name>
<name>
<surname>Marchant</surname> <given-names>T</given-names>
</name>
<name>
<surname>Saunderson</surname> <given-names>C</given-names>
</name>
<name>
<surname>McWilliam</surname> <given-names>A</given-names>
</name>
<name>
<surname>Banfill</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Moving beyond mean heart dose: The importance of cardiac substructures in radiation therapy toxicity</article-title>. <source>J Med Imaging Radiat Oncol</source>. (<year>2024</year>), <page-range>947&#x2013;86</page-range>. John Wiley and Sons Inc. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/1754-9485.13737</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McWilliam</surname> <given-names>A</given-names>
</name>
<name>
<surname>Kennedy</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hodgson</surname> <given-names>C</given-names>
</name>
<name>
<surname>Vasquez Osorio</surname> <given-names>E</given-names>
</name>
<name>
<surname>Faivre-Finn</surname> <given-names>C</given-names>
</name>
<name>
<surname>van Herk</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Radiation dose to heart base linked with poorer survival in lung cancer patients</article-title>. <source>Eur J Cancer</source>. (<year>2017</year>) <volume>85</volume>:<page-range>106&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejca.2017.07.053</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McWilliam</surname> <given-names>A</given-names>
</name>
<name>
<surname>Khalifa</surname> <given-names>J</given-names>
</name>
<name>
<surname>Vasquez Osorio</surname> <given-names>E</given-names>
</name>
<name>
<surname>Banfill</surname> <given-names>K</given-names>
</name>
<name>
<surname>Abravan</surname> <given-names>A</given-names>
</name>
<name>
<surname>Faivre-Finn</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Novel methodology to investigate the effect of radiation dose to heart substructures on overall survival</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>2020</year>) <volume>108</volume>:<page-range>1073&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijrobp.2020.06.031</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marchant</surname> <given-names>T</given-names>
</name>
<name>
<surname>Wood</surname> <given-names>J</given-names>
</name>
<name>
<surname>Banfill</surname> <given-names>K</given-names>
</name>
<name>
<surname>McWilliam</surname> <given-names>A</given-names>
</name>
<name>
<surname>Price</surname> <given-names>G</given-names>
</name>
<name>
<surname>Faivre-Finn</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Dosimetric impact of sparing base of heart on organ at risk doses during lung radiotherapy</article-title>. <source>Radiother Oncol</source>. (<year>2025</year>) <volume>202</volume>:<page-range>1&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.radonc.2024.110654</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghobadi</surname> <given-names>G</given-names>
</name>
<name>
<surname>Bartelds</surname> <given-names>B</given-names>
</name>
<name>
<surname>van der Veen</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Dickinson</surname> <given-names>MG</given-names>
</name>
<name>
<surname>Brandenburg</surname> <given-names>S</given-names>
</name>
<name>
<surname>Berger</surname> <given-names>RMF</given-names>
</name>
<etal/>
</person-group>. <article-title>Lung irradiation induces pulmonary vascular remodelling resembling pulmonary arterial hypertension</article-title>. <source>Thorax</source>. (<year>2012</year>) <volume>67</volume>:<page-range>334&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/thoraxjnl-2011-200346</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Luijk</surname> <given-names>P</given-names>
</name>
<name>
<surname>Novakova-Jiresova</surname> <given-names>A</given-names>
</name>
<name>
<surname>Faber</surname> <given-names>H</given-names>
</name>
<name>
<surname>Schippers</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Kampinga</surname> <given-names>HH</given-names>
</name>
<name>
<surname>Meertens</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Radiation damage to the heart enhances early radiation-induced lung function loss</article-title>. <source>Cancer Res</source>. (<year>2005</year>) <volume>65</volume>:<page-range>6509&#x2013;11</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-0786</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiedemann</surname> <given-names>J</given-names>
</name>
<name>
<surname>Paruchuru</surname> <given-names>SK</given-names>
</name>
<name>
<surname>den Boef</surname> <given-names>LE</given-names>
</name>
<name>
<surname>Brouwer</surname> <given-names>U</given-names>
</name>
<name>
<surname>Sillj&#xe9;</surname> <given-names>HHW</given-names>
</name>
<name>
<surname>Schouten</surname> <given-names>EM</given-names>
</name>
<etal/>
</person-group>. <article-title>Sparing of the heart facilitates recovery from cardiopulmonary side effects after thoracic irradiation</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>2024</year>) <volume>121</volume>:<page-range>191&#x2013;201</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijrobp.2024.07.2330</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghobadi</surname> <given-names>G</given-names>
</name>
<name>
<surname>van der Veen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bartelds</surname> <given-names>B</given-names>
</name>
<name>
<surname>De Boer</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Dickinson</surname> <given-names>MG</given-names>
</name>
<name>
<surname>De Jong</surname> <given-names>JR</given-names>
</name>
<etal/>
</person-group>. <article-title>Physiological interaction of heart and lung in thoracic irradiation</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>2012</year>) <volume>84</volume>:<page-range>e639&#x2013;46</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijrobp.2012.07.2362</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname> <given-names>GM</given-names>
</name>
<name>
<surname>O&#x2019;Connor</surname> <given-names>J</given-names>
</name>
<name>
<surname>Harbinson</surname> <given-names>M</given-names>
</name>
<name>
<surname>Duane</surname> <given-names>F</given-names>
</name>
<name>
<surname>McCann</surname> <given-names>C</given-names>
</name>
<name>
<surname>McKavanagh</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>The association of incidental radiation dose to the heart base with overall survival and cardiac events after curative-intent radiotherapy for non-small cell lung cancer: results from the NI-HEART study</article-title>. <source>Clin Oncol</source>. (<year>2024</year>) <volume>36</volume>:<page-range>119&#x2013;27</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.clon.2023.11.029</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verhaegen</surname> <given-names>F</given-names>
</name>
<name>
<surname>Butterworth</surname> <given-names>KT</given-names>
</name>
<name>
<surname>Chalmers</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Coppes</surname> <given-names>RP</given-names>
</name>
<name>
<surname>de Ruysscher</surname> <given-names>D</given-names>
</name>
<name>
<surname>Dobiasch</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Roadmap for precision preclinical x-ray radiation studies</article-title>. <source>Phys Med Biol</source>. (<year>2023</year>) <volume>68</volume>:<page-range>1&#x2013;42</page-range>. Institute of Physics. doi:&#xa0;<pub-id pub-id-type="doi">10.1088/1361-6560/acaf45</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname> <given-names>KH</given-names>
</name>
<name>
<surname>Ghita</surname> <given-names>M</given-names>
</name>
<name>
<surname>Dubois</surname> <given-names>LJ</given-names>
</name>
<name>
<surname>de Ruysscher</surname> <given-names>D</given-names>
</name>
<name>
<surname>Prise</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Verhaegen</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>A scoping review of small animal image-guided radiotherapy research: Advances, impact and future opportunities in translational radiobiology</article-title>. <source>Clin Transl Radiat Oncol</source>. (<year>2022</year>) <volume>34</volume>:<page-range>112&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ctro.2022.04.004</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butterworth</surname> <given-names>KT</given-names>
</name>
</person-group>. <article-title>Evolution of the supermodel: progress in modelling radiotherapy response in mice</article-title>. <source>Clin Oncol</source>. (<year>2019</year>) <volume>31</volume>:<page-range>272&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.clon.2019.02.008</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghita</surname> <given-names>M</given-names>
</name>
<name>
<surname>Gill</surname> <given-names>EK</given-names>
</name>
<name>
<surname>Walls</surname> <given-names>GM</given-names>
</name>
<name>
<surname>Edgar</surname> <given-names>KS</given-names>
</name>
<name>
<surname>McMahon</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Osorio</surname> <given-names>EV</given-names>
</name>
<etal/>
</person-group>. <article-title>Cardiac sub-volume targeting demonstrates regional radiosensitivity in the mouse heart</article-title>. <source>Radiother Oncol</source>. (<year>2020</year>) <volume>152</volume>:<page-range>216&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.radonc.2020.07.016</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghita-Pettigrew</surname> <given-names>M</given-names>
</name>
<name>
<surname>Edgar</surname> <given-names>KS</given-names>
</name>
<name>
<surname>Kuburas</surname> <given-names>R</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>KH</given-names>
</name>
<name>
<surname>Walls</surname> <given-names>GM</given-names>
</name>
<name>
<surname>Facchi</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Dose-dependent changes in cardiac function, strain and remodelling in a preclinical model of heart base irradiation</article-title>. <source>Radiother Oncol</source>. (<year>2024</year>) <volume>193</volume>:<page-range>1&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.radonc.2024.110113</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname> <given-names>GM</given-names>
</name>
<name>
<surname>Ghita</surname> <given-names>M</given-names>
</name>
<name>
<surname>Queen</surname> <given-names>R</given-names>
</name>
<name>
<surname>Edgar</surname> <given-names>KS</given-names>
</name>
<name>
<surname>Gill</surname> <given-names>EK</given-names>
</name>
<name>
<surname>Kuburas</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Spatial gene expression changes in the mouse heart after base-targeted irradiation</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>2023</year>) <volume>115</volume>:<page-range>453&#x2013;63</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijrobp.2022.08.031</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>du Sert</surname> <given-names>NP</given-names>
</name>
<name>
<surname>Ahluwalia</surname> <given-names>A</given-names>
</name>
<name>
<surname>Alam</surname> <given-names>S</given-names>
</name>
<name>
<surname>Avey</surname> <given-names>MT</given-names>
</name>
<name>
<surname>Baker</surname> <given-names>M</given-names>
</name>
<name>
<surname>Browne</surname> <given-names>WJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Reporting animal research: Explanation and elaboration for the arrive guidelines 2.0</article-title>. <source>PloS Biol</source>. (<year>2020</year>) <volume>18</volume>:<page-range>1&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pbio.3000411</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname> <given-names>GM</given-names>
</name>
<name>
<surname>O&#x2019;Kane</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ghita</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kuburas</surname> <given-names>R</given-names>
</name>
<name>
<surname>McGarry</surname> <given-names>CK</given-names>
</name>
<name>
<surname>Cole</surname> <given-names>AJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Murine models of radiation cardiotoxicity: A systematic review and recommendations for future studies</article-title>. <source>Radiother Oncol</source>. (<year>2022</year>) <volume>173</volume>:<fpage>19</fpage>&#x2013;<lpage>31</lpage>. Elsevier Ireland Ltd. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.radonc.2022.04.030</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aukett</surname> <given-names>RJ</given-names>
</name>
<name>
<surname>Burns</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Greener</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Harrison</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Moretti</surname> <given-names>C</given-names>
</name>
<name>
<surname>Nahum</surname> <given-names>AE</given-names>
</name>
<etal/>
</person-group>. <article-title>Addendum to the IPEMB code of practice for the determination of absorbed dose for x-rays below 300 kV generating potential (0.035 mm Al-4 mm Cu HVL)</article-title>. <source>Phys Med Biol</source>. (<year>2005</year>) <volume>50</volume>:<page-range>2739&#x2013;48</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1088/0031-9155/50/12/001</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>McLaughlin</surname> <given-names>D</given-names>
</name>
<name>
<surname>Robinson</surname> <given-names>E</given-names>
</name>
<name>
<surname>Harvey</surname> <given-names>AP</given-names>
</name>
<name>
<surname>Hookham</surname> <given-names>MB</given-names>
</name>
<name>
<surname>Shah</surname> <given-names>AM</given-names>
</name>
<etal/>
</person-group>. <article-title>Nox2 Nadph oxidaze promotes pathologic cardiac remodelling associated with doxorubicin chemotherapy</article-title>. <source>Cancer Res</source>. (<year>2011</year>) <volume>70</volume>:<page-range>9287&#x2013;97</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2664</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghita</surname> <given-names>M</given-names>
</name>
<name>
<surname>Dunne</surname> <given-names>VL</given-names>
</name>
<name>
<surname>McMahon</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Osman</surname> <given-names>SO</given-names>
</name>
<name>
<surname>Small</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Weldon</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Preclinical evaluation of dose-volume effects and lung toxicity occurring in and out-of-field</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. (<year>2019</year>) <volume>103</volume>:<page-range>1231&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijrobp.2018.12.010</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuleshov</surname> <given-names>MV</given-names>
</name>
<name>
<surname>Jones</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Rouillard</surname> <given-names>AD</given-names>
</name>
<name>
<surname>Fernandez</surname> <given-names>NF</given-names>
</name>
<name>
<surname>Duan</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Enrichr: a comprehensive gene set enrichment analysis web server 2016 update</article-title>. <source>Nucleic Acids Res</source>. (<year>2016</year>) <volume>44</volume>:<page-range>W90&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/nar/gkw377</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Der Veen</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Faber</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ghobadi</surname> <given-names>G</given-names>
</name>
<name>
<surname>Brandenburg</surname> <given-names>S</given-names>
</name>
<name>
<surname>Langendijk</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Coppes</surname> <given-names>RP</given-names>
</name>
<etal/>
</person-group>. <article-title>Decreasing irradiated rat lung volume changes dose-limiting toxicity from early to late effects</article-title>. <source>Radiat Oncol Biol</source>. (<year>2016</year>) <volume>94</volume>:<page-range>163&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijrobp.2015.09.034</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wirsd&#xf6;rfer</surname> <given-names>F</given-names>
</name>
<name>
<surname>Jendrossek</surname> <given-names>V</given-names>
</name>
</person-group>. <article-title>Modeling DNA damage-induced pneumopathy in mice: insight from danger signaling cascades</article-title>. <source>Radiat Oncol</source>. (<year>2017</year>) <volume>12</volume>:<fpage>142</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13014-017-0865-1</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghita</surname> <given-names>M</given-names>
</name>
<name>
<surname>Dunne</surname> <given-names>V</given-names>
</name>
<name>
<surname>Hanna</surname> <given-names>GG</given-names>
</name>
<name>
<surname>Prise</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Butterworth</surname> <given-names>KT</given-names>
</name>
</person-group>. <article-title>Preclinical models of radiation-induced lung damage: Challenges and opportunities for small animal radiotherapy</article-title>. <source>Br J Radiol</source>. (<year>2019</year>) <volume>92</volume>:<page-range>1&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1259/bjr.20180473</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mann</surname> <given-names>DL</given-names>
</name>
</person-group>. <article-title>Innate immunity and the failing heart: The cytokine hypothesis revisited</article-title>. <source>Circ Res</source>. (<year>2015</year>) <volume>116</volume>:<page-range>1254&#x2013;68</page-range>. Lippincott Williams and Wilkins. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.302317</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharygin</surname> <given-names>D</given-names>
</name>
<name>
<surname>Koniaris</surname> <given-names>LG</given-names>
</name>
<name>
<surname>Wells</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zimmers</surname> <given-names>TA</given-names>
</name>
<name>
<surname>Hamidi</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Role of CD14 in human disease</article-title>. <source>Immunology</source>. (<year>2023</year>) <volume>169</volume>:<page-range>260&#x2013;70</page-range>. John Wiley and Sons Inc. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/imm.13634</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zanoni</surname> <given-names>I</given-names>
</name>
<name>
<surname>Granucci</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Role of CD14 in host protection against infections and in metabolism regulation</article-title>. <source>Front Cell Infect Microbiol</source>. (<year>2013</year>) <volume>4</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcimb.2013.00032</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Kindi</surname> <given-names>SG</given-names>
</name>
<name>
<surname>Buzkova</surname> <given-names>P</given-names>
</name>
<name>
<surname>Shitole</surname> <given-names>SG</given-names>
</name>
<name>
<surname>Reiner</surname> <given-names>AP</given-names>
</name>
<name>
<surname>Garg</surname> <given-names>PK</given-names>
</name>
<name>
<surname>Gottdiener</surname> <given-names>JS</given-names>
</name>
<etal/>
</person-group>. <article-title>Soluble CD14 and risk of heart failure and its subtypes in older adults</article-title>. <source>J Card Fail</source>. (<year>2020</year>) <volume>26</volume>:<fpage>410</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cardfail.2020.03.003</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Sai</surname> <given-names>B</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment</article-title>. <source>Cancer Biol Ther</source>. (<year>2020</year>) <volume>21</volume>:<fpage>61</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/15384047.2019.1665952</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>da Rocha</surname> <given-names>RG</given-names>
</name>
<name>
<surname>Santos</surname> <given-names>EMS</given-names>
</name>
<name>
<surname>Santos</surname> <given-names>EM</given-names>
</name>
<name>
<surname>Gomes</surname> <given-names>ESB</given-names>
</name>
<name>
<surname>Ramos</surname> <given-names>GV</given-names>
</name>
<name>
<surname>Aguiar</surname> <given-names>KM</given-names>
</name>
<etal/>
</person-group>. <article-title>Leptin impairs the therapeutic effect of ionizing radiation in oral squamous cell carcinoma cells</article-title>. <source>J Oral Pathol Med</source>. (<year>2018</year>) <volume>48</volume>:<fpage>17</fpage>&#x2013;<lpage>23</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/jop.2019.48.issue-1</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>F</given-names>
</name>
<name>
<surname>Li</surname> <given-names>F</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>B</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Autocrined leptin promotes proliferation of non-small cell lung cancer (NSCLC) via PI3K/AKT and p53 pathways</article-title>. <source>Ann Transl Med</source>. (<year>2021</year>) <volume>9</volume>:<fpage>568</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.21037/atm-20-7482</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ignatescu</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Gharehbaghi-Schnell</surname> <given-names>E</given-names>
</name>
<name>
<surname>Hassan</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rezaie-Majd</surname> <given-names>S</given-names>
</name>
<name>
<surname>Korschineck</surname> <given-names>I</given-names>
</name>
<name>
<surname>Schleef</surname> <given-names>RR</given-names>
</name>
<etal/>
</person-group>. <article-title>Expression of the angiogenic protein, platelet-derived endothelial cell growth factor, in coronary atherosclerotic plaques <italic>in vivo</italic> correlation of lesional microvessel density and constrictive vascular remodeling</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. (<year>1999</year>) <volume>19</volume>:<page-range>2340&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1161/01.atv.19.10.2340</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collins</surname> <given-names>AR</given-names>
</name>
<name>
<surname>Schnee</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>S</given-names>
</name>
<name>
<surname>Fishbein</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Bruemmer</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Osteopontin modulates angiotensin II- induced fibrosis in the intact murine heart</article-title>. <source>J Am Coll Cardiol</source>. (<year>2004</year>) <volume>43</volume>:<page-range>1698&#x2013;705</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jacc.2003.11.058</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Psarras</surname> <given-names>S</given-names>
</name>
<name>
<surname>Mavroidis</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sanoudou</surname> <given-names>D</given-names>
</name>
<name>
<surname>Davos</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Xanthou</surname> <given-names>G</given-names>
</name>
<name>
<surname>Varela</surname> <given-names>AE</given-names>
</name>
<etal/>
</person-group>. <article-title>Regulation of adverse remodelling by osteopontin in a genetic heart failure model</article-title>. <source>Eur Heart J</source>. (<year>2012</year>) <volume>33</volume>:<page-range>1954&#x2013;63</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/eurheartj/ehr119</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Stamenkovic</surname> <given-names>I</given-names>
</name>
</person-group>. <article-title>Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-&#x3b2; and promotes tumor invasion and angiogenesis</article-title>. <source>Genes Dev</source>. (<year>2000</year>) <volume>14</volume>:<fpage>163</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1101/gad.14.2.163</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname> <given-names>IK</given-names>
</name>
<name>
<surname>Letterio</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Gorham</surname> <given-names>JD</given-names>
</name>
</person-group>. <article-title>TGF-&#x3b2;1 inhibition of IFN-&#x3b3;-induced signaling and Th1 gene expression in CD4+ T cells is Smad3 independent but MAP kinase dependent</article-title>. <source>Mol Immunol</source>. (<year>2007</year>) <volume>44</volume>:<fpage>3283</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.molimm.2007.02.024</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wiedemann</surname> <given-names>J</given-names>
</name>
<name>
<surname>Coppes</surname> <given-names>RP</given-names>
</name>
<name>
<surname>van Luijk</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Radiation-induced cardiac side-effects: The lung as target for interacting damage and intervention</article-title>. <source>Front Oncol</source>. (<year>2022</year>) <volume>12</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2022.931023</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quindry</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Ballmann</surname> <given-names>CG</given-names>
</name>
<name>
<surname>Epstein</surname> <given-names>EE</given-names>
</name>
<name>
<surname>Selsby</surname> <given-names>JT</given-names>
</name>
</person-group>. <article-title>Plethysmography measurements of respiratory function in conscious unrestrained mice</article-title>. <source>J Physiol Sci</source>. (<year>2016</year>) <volume>66</volume>:<page-range>157&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12576-015-0408-1</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>